Skip to main content
. 2023 Oct 6;16:4399–4411. doi: 10.2147/JIR.S428218

Table 2.

Number of PLA2R Antibody-Associated MN Patients Achieving Immunological Remission Within 6 Months After Treated with Rituximab for One Cycle

Time (Months) Number of Patients Achieving Immunological Remission [n (%)]
0 0 (0.0)
1 17 (16.0)
2 41 (38.7)
3 46 (43.4)
4 50 (47.2)
5 54 (50.9)
6 75 (70.8)

Note: Data presented as number (percentage).

Abbreviations: MN, membranous nephropathy; PLA2R antibody, phospholipase A2 receptor antibody.